PE20250267A1 - ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC) - Google Patents
ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC)Info
- Publication number
- PE20250267A1 PE20250267A1 PE2023002896A PE2023002896A PE20250267A1 PE 20250267 A1 PE20250267 A1 PE 20250267A1 PE 2023002896 A PE2023002896 A PE 2023002896A PE 2023002896 A PE2023002896 A PE 2023002896A PE 20250267 A1 PE20250267 A1 PE 20250267A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- alkyl
- fluorine atoms
- sgc
- fluoroalkyl substituted
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title abstract 3
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title abstract 3
- 239000003119 guanylate cyclase activator Substances 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a estimuladores de la guanilil ciclasa soluble (sGC), o sales farmaceuticamente aceptables de los mismos y formulaciones farmaceuticas que los comprenden y sus usos, solo o en combinacion, para el tratamiento de enfermedades, donde es deseable un aumento en la concentracion del oxido nitrico (NO) y/o un aumento en la concentracion del monofosfato de guanosina ciclico (cGMP), o ambas cosas, o un aumento de la expresion de la ruta del NO. En particular, se refiere a un compuesto caracterizado porque por la Formula I: o una sal farmaceuticamente aceptable del mismo, donde: JC es H, halogeno, C1-6 alquilo y C1-6 fluoroalquilo sustituido con entre 1 y 3 atomos de fluor; X es N o C(JC1); JC1 es H, halogeno, C1-6 alquilo y C1-6 fluoroalquilo sustituido con entre 1 y 3 atomos de fluor; cada JB es independientemente H, halogeno, C1-6 alquilo y C1-6 fluoroalquilo sustituido con entre 1 y 3 atomos de fluor; JD es H, halogeno, C1-6 alquilo y C1-6 fluoroalquilo sustituido con entre 1 y 3 atomos de fluor; y n es un numero entero entre 0, 1, 2, 3 o 4, con la condicion de que el compuesto no sea (a), (b), (c), entre otros.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177020P | 2021-04-20 | 2021-04-20 | |
| US202163229248P | 2021-08-04 | 2021-08-04 | |
| PCT/US2022/025310 WO2022225903A1 (en) | 2021-04-20 | 2022-04-19 | Sgc stimulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250267A1 true PE20250267A1 (es) | 2025-01-29 |
Family
ID=81579984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002896A PE20250267A1 (es) | 2021-04-20 | 2022-04-19 | ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240208979A1 (es) |
| EP (1) | EP4326722A1 (es) |
| JP (1) | JP2024515119A (es) |
| KR (1) | KR20240058047A (es) |
| AU (1) | AU2022261862A1 (es) |
| BR (1) | BR112023021851A2 (es) |
| CA (1) | CA3216127A1 (es) |
| CL (1) | CL2023003105A1 (es) |
| CO (1) | CO2023015528A2 (es) |
| CR (1) | CR20230532A (es) |
| IL (1) | IL307865A (es) |
| MX (1) | MX2023012398A (es) |
| PE (1) | PE20250267A1 (es) |
| TW (1) | TW202309038A (es) |
| WO (1) | WO2022225903A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024086179A1 (en) * | 2022-10-18 | 2024-04-25 | Tisento Therapeutics, Inc. | Pyrimidine sgc stimulators |
| CN120112293A (zh) * | 2022-10-18 | 2025-06-06 | 帝善多制药公司 | 使用sGC刺激剂治疗线粒体疾病 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| WO2000002851A1 (en) | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| JP2011510082A (ja) | 2008-01-24 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | アンジオテンシンｉｉ受容体拮抗薬 |
| CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2010099054A2 (en) | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| NZ603884A (en) | 2010-05-27 | 2014-06-27 | Merck Sharp & Dohme | Soluble guanylate cyclase activators |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP3152214B1 (en) | 2014-06-04 | 2020-01-29 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| US10213429B2 (en) * | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| CA3035210A1 (en) | 2016-09-02 | 2018-03-08 | Ironwood Pharmaceuticals, Inc. | Fused bicyclic sgc stimulators |
| JP7337067B2 (ja) | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス，インコーポレーテッド | ｓＧＣ刺激薬 |
-
2022
- 2022-04-19 TW TW111114883A patent/TW202309038A/zh unknown
- 2022-04-19 CA CA3216127A patent/CA3216127A1/en active Pending
- 2022-04-19 CR CR20230532A patent/CR20230532A/es unknown
- 2022-04-19 EP EP22721237.0A patent/EP4326722A1/en active Pending
- 2022-04-19 IL IL307865A patent/IL307865A/en unknown
- 2022-04-19 BR BR112023021851A patent/BR112023021851A2/pt unknown
- 2022-04-19 PE PE2023002896A patent/PE20250267A1/es unknown
- 2022-04-19 WO PCT/US2022/025310 patent/WO2022225903A1/en active Application Filing
- 2022-04-19 MX MX2023012398A patent/MX2023012398A/es unknown
- 2022-04-19 US US18/287,612 patent/US20240208979A1/en active Pending
- 2022-04-19 KR KR1020237039779A patent/KR20240058047A/ko active Pending
- 2022-04-19 JP JP2023565192A patent/JP2024515119A/ja active Pending
- 2022-04-19 AU AU2022261862A patent/AU2022261862A1/en active Pending
-
2023
- 2023-10-18 CL CL2023003105A patent/CL2023003105A1/es unknown
- 2023-11-17 CO CONC2023/0015528A patent/CO2023015528A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240208979A1 (en) | 2024-06-27 |
| CL2023003105A1 (es) | 2024-03-22 |
| CO2023015528A2 (es) | 2024-02-26 |
| AU2022261862A2 (en) | 2024-07-18 |
| KR20240058047A (ko) | 2024-05-03 |
| AU2022261862A1 (en) | 2023-11-30 |
| EP4326722A1 (en) | 2024-02-28 |
| CR20230532A (es) | 2024-03-22 |
| JP2024515119A (ja) | 2024-04-04 |
| MX2023012398A (es) | 2024-03-13 |
| BR112023021851A2 (pt) | 2024-02-06 |
| CA3216127A1 (en) | 2022-10-27 |
| TW202309038A (zh) | 2023-03-01 |
| IL307865A (en) | 2023-12-01 |
| WO2022225903A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250267A1 (es) | ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC) | |
| CO2019001760A2 (es) | Estimuladores de sgc | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| PE20190910A1 (es) | Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih | |
| CO2022011728A2 (es) | Composiciones y usos de glp-1 | |
| EA202091502A1 (ru) | СТИМУЛЯТОРЫ sGC | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| ES2145113T3 (es) | Dispositivo para la administracion vaginal de tamoxifeno o sus analogos. | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| PE20190347A1 (es) | Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| ES2052015T3 (es) | Un metodo de preparacion de una composicion farmaceutica. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| AR125378A1 (es) | Estimuladores de guanilil ciclasa soluble (sgc) | |
| MX2024010321A (es) | Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos | |
| AR115921A1 (es) | Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile | |
| GB1104885A (en) | Method for the treatment of helminth infestations | |
| AR110319A1 (es) | Composición para el tratamiento de la osteoartritis | |
| AR121285A1 (es) | N4-hidroxicitidina y sus derivados y usos antivirales relacionados con la misma | |
| AR125221A2 (es) | Estimuladores de sgc | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| PT1137420E (pt) | Utilização de uma associação de uma purina e um agente dador de monóxido de azoto para a prevenção ou tratamento de disfunções sexuais. | |
| AR121415A1 (es) | INHIBIDORES DE LA QUINASA p38 QUE REDUCEN LA EXPRESIÓN DE DUX4 Y DE LOS GENES CORRIENTE ABAJO PARA USO EN EL TRATAMIENTO DE FSHD |